Effects of different angiotensins during acute, double blockade of the renin system in conscious dogs.
Evidence of biological activity of fragments of ANG II is accumulating. Fragments considered being inactive degradation products might mediate actions previously attributed to ANG II. The study aimed to determine whether angiotensin fragments exert biological activity when administered in amounts equimolar to physiological doses of ANG II. Cardiovascular, endocrine, and renal effects of ANG II, ANG III, ANG IV, and ANG-(1-7) (6 pmol.kg-1.min-1) were investigated in conscious dogs during acute inhibition of angiotensin I-converting enzyme (enalaprilate) and aldosterone (canrenoate). Furthermore, ANG III was investigated by step-up infusion (30 and 150 pmol.kg-1.min-1). Arterial plasma concentrations [ANG immunoreactivity (IR)] were determined by an ANG II antibody cross-reacting with ANG III and ANG IV. Metabolic clearance rates were higher for ANG III and ANG IV (391 +/- 19 and 274 +/- 13 ml.kg-1.min-1, respectively) than for ANG II (107 +/- 13 ml.kg-1.min-1). ANG II increased ANG IR by 60 +/- 7 pmol/ml, blood pressure by 30%, increased plasma aldosterone markedly (to 345 +/- 72 pg/ml), and plasma vasopressin transiently, while reducing glomerular filtration rate (40 +/- 2 to 33 +/- 2 ml/min), sodium excretion (50 +/- 7 to 16 +/- 4 micromol/min), and urine flow. Equimolar amounts of ANG III induced similar antinatriuresis (57 +/- 8 to 19 +/- 3 micromol/min) and aldosterone secretion (to 268 +/- 71 pg/ml) at much lower ANG IR increments ( approximately 1/7) without affecting blood pressure, vasopressin, or glomerular filtration rate. The effects of ANG III exhibited complex dose-response relations. ANG IV and ANG-(1-7) were ineffective. It is concluded that 1) plasma clearances of ANG III and ANG IV are higher than those of ANG II; 2) ANG III is more potent than ANG II in eliciting immediate sodium and potassium retention, as well as aldosterone secretion, particularly at low concentrations; and 3) the complexity of the ANG III dose-response relationships provides indirect evidence that several effector mechanisms are involved.
Wamberg
Christian
C
Dept. of Physiology and Pharmacology, Institute of Medical Biology, 21 Winsløwparken, DK-5000 Odense, Denmark.
Plovsing
Ronni R
RR
Sandgaard
Niels C F
NC
Bie
Peter
P
D000450:Aldosterone / Q000097:blood; D000803:Angiotensin I / Q000493:pharmacokinetics / Q000494:pharmacology; D000804:Angiotensin II / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology*; D000805:Angiotensin III / Q000493:pharmacokinetics / Q000494:pharmacology; D000818:Animals; D000959:Antihypertensive Agents / Q000493:pharmacokinetics / Q000494:pharmacology; D009320:Atrial Natriuretic Factor / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects; D003243:Consciousness; D004231:Diuresis / Q000187:drug effects; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D009318:Natriuresis / Q000187:drug effects; D010446:Peptide Fragments / Q000493:pharmacokinetics / Q000494:pharmacology; D012083:Renin / Q000502:physiology*; D012084:Renin-Angiotensin System / Q000187:drug effects* / Q000502:physiology*; D014662:Vasoconstrictor Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D014667:Vasopressins / Q000097:blood
D000959:Antihypertensive Agents; D010446:Peptide Fragments; D014662:Vasoconstrictor Agents; D014667:Vasopressins; D000804:Angiotensin II; D000805:Angiotensin III; C012877:angiotensin II, des-Asp(1)-des-Arg(2)-Ile(5)-; D000450:Aldosterone; D009320:Atrial Natriuretic Factor; D000803:Angiotensin I; D012083:Renin; C118790:angiotensin I (1-7)